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in Hematopoietic Stem Cell Transplantation Programs
Jeffrey R. Schriber,1 Claudio Anasetti,2 Helen E. Heslop,3 Alan K. Leahigh4During the past decade, the demand for hematopoietic stem cell transplantation has grown dramatically, and
there are expectations that this will continue or even accelerate over the next decade. This prompts a variety
of questions about the ability of the health care system to accommodate the increased demands on trans-
plantation centers; for example, what is the current patient capacity of transplantation programs, and
how much elasticity do they have to accept a larger volume of patients? An informal survey of a sample of
medical directors of transplantation programs found that existing facilities might be able to increase their
patient volume by about 7%. Expanding much beyond that limit will require an infusion of resources to
enlarge current programs and/or establish new programs.
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According to the Center for International Blood
and Marrow Transplant Research (CIBMTR), an esti-
mated 18,600 hematopoietic stem cell transplantations
(HSCTs) were performed in theUnited States in 2006,
including about 12,500 autologous, 3800 related allo-
geneic, and 2300 unrelated allogeneic HSCTs (Center
for International Blood and Marrow Transplant
Research, unpublished data, 2009). The number of
HSCTs performed in the United States increased by
24% over the 5-year period from 2002 to 2006. The
most dramatic growth occurred in adult allogeneic
HSCT. The National Marrow Donor Program
(NMDP) reported facilitating approximately 2160
adult unrelated allogeneic HSCTs inU.S. transplanta-
tion centers in 2007, compared with approximately
760 in 1997. The number of pediatric HSCTs also
has increased significantly, from approximately 380Department of Blood andMarrow Transplantation, Ban-
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6/j.bbmt.2010.02.010in 1997 to approximately 730 in 2007 (National
Marrow Donor Program, unpublished data, 2009).Reasons for Anticipated Growth
There are many reasons to expect continued
increases in the number of HSCTs performed in the
coming decade. Current tends include the following:
 HSCT is increasingly effective, with continual
improvements in treatment outcome.
 HSCT is increasingly safer, with constantly favor-
able survival rates.
 The number of diseases for which HSCT is indi-
cated continues to grow.
 The sources of donor cells and the number of suit-
able matches are expanding.
 An aging population is increasing the proportion of
people who are susceptible to diseases for which
HSCT is indicated.
 Modified transplantation regimens have facilitated
safer procedures despite an increase in the median
patient age.
 Proposed national health insurance reforms cur-
rently under debate in Congress may expand the
number of insured patients and reduce economic
barriers for more patients.
Anticipating an increasing need for hematopoietic
stem cell donors, the NMDP has launched a campaign
designed to increase the number of registered donors
to accommodate 10,000 unrelated allogeneic HSCTs
per year by 2015, more than double the 4300 facilitated
in 2008.595
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A significant concern related to the anticipated
increase in HSCTs is whether sufficient hematologists
and oncologists specifically trained and experienced in
cellular therapies will be available to meet the demand.
Gajewski et al. [1] explored this question in a recent
commentary in which they estimated the need for an
expanded transplantation physician workforce. They
estimated the current number of adult and pediatric
transplantation physicians at 959 and 156, respectively.
Their projections indicated that even with nonacceler-
ated, straight-line growth, 1264 new adult transplanta-
tion physicians and 94 new pediatric transplantation
physicians will be needed by the year 2020. These
needs are particularly daunting considering the
anticipated shortage of physicians across nearly all spe-
cialties and primary care, the 10-12 years of postunder-
graduate training required for subspecialization in
HSCT, and the increasing barriers to immigration to
the United States faced by foreign-trained physicians.
Exacerbating the transplantation workforce short-
age is the fact that most of the growth is expected to be
in allogeneic HSCT. Current trends are to perform
allogeneic HSCT in older patients and those with
comorbidities that once would have been contradic-
tions to transplantation. The increased success in
addressing some early causes of mortality has resulted
in the welcome consequence of an increased need for
post-HSCT management. These patients often have
multiple medical issues related to HSCT that might
preclude a return to the primary oncologist. These
patients often are seen more frequently and require
more complex routine and unexpected clinic visits, as
well as more complicated late hospitalizations.
Transplantation Facility Expansion
In addition to concerns about workforce shortage,
there is the question of how many additional patients
can be absorbed by current transplantation programs.
Expressed another way, to what degree are current
transplantation programs able to accept larger num-
bers of patients?METHODS
In an attempt to answer the foregoing question,
an informal survey was conducted to quantify the
current patient volume and capacity of transplantation
programs. Information was gathered from 31 trans-
plantation programs representing nearly 7,000 trans-
plantation procedures in 2008. The survey was
conducted at the behest of the American Society for
Blood andMarrowTransplantation’s (ASBMT) Board
of Directors.
The survey sample included the 20 U.S. transplan-
tation programs or centers with the highest volume ofallogeneic HSCTs and the 20 U.S. programs or cen-
ters with the highest volume of autologous HSCTs
in 2002-2006, as identified by the CIBMTR. Twelve
centers were on both lists; thus, a total of 28 centers
were initially identified. Added to the sample were 6
centers with smaller patient volumes, selected to add
their dimension and representation to the sample. In
all, 34 centers were invited to participate in the survey.
A questionnaire addressing current patient volume
and expansion potential were sent by e-mail to the
medical directors of the 34 centers in May 2008. The
questions were brief, and the questionnaire was
designed to be completed in about 10 minutes.
Follow-up telephone calls helped to ensure a high
response rate. Information solicited included the num-
ber of transplantation procedures performed annually,
the number of physicians and ‘‘physician extenders’’
(eg, physician assistants, nurse practitioners), the
nurse-to-patient ratio, and the number of additional
transplantations that could be performed with current
resources and staffing levels. Also included were ques-
tions about factors that might limit expansion, changes
foreseen in the transplantation field, and how the
ASBMT could help manage those changes.RESULTS
Thirty-one of the 34 centers completed the survey,
for an overall response rate of 91%. Included among
the respondents were medical directors at 19 of the
20 largest allogeneic HSCT programs, 6 of the 8 larg-
est autologous HSCT programs, and all 6 of the
smaller programs. In total, the centers represented
6937 transplantations, 313 transplantation physicians,
and 204 physician extenders.
One of the questions asked was whether the center
would need additional resources to increase the
number of patients served. The centers reporting no
need for additional resources were then asked to
project how many additional transplantations they
could perform.
Eleven of the 19 large allogeneic HSCT programs
reported that they were already operating at capacity
and could not accept a larger patient volume without
increased resources. The other 8 of these centers to-
gether estimated being able to perform 210 additional
transplantations. One of the 6 large autologous HSCT
centers reported operating at capacity. The other 5
centers together estimated that they could perform
274 additional transplantations. Two of these centers
indicated that the additional patients would severely
strain current staff and resources, however, so this
number might be overly optimistic. Among the 6
smaller centers surveyed, 4 reported being at capacity,
and the other 2 reported the ability to increase their
annual patient volume by a total of 30 patients. Adding
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volume of 6937 patients reported the capacity to
perform 514 additional transplantations per year, an
increase of about 7%.
Among the other survey findings were the
following:
 The median ratio of annual transplantations per
physician was 25:1.
 Every center reported using ‘‘physician extenders,’’
such as physician assistants and nurse practitioners.
Combining these personnel with physicians, the
median ratio of annual transplantations per health
professional was 14:1.
 Thirteen of the 31 centers (42%) were actively look-
ing for additional medical personnel, and most re-
ported having difficulty filling current staffing needs.
 Transplantation physicians are the most difficult to
find, although shortages of physician extenders,
nurses, pharmacists, and stem cell laboratory staff
were reported as well.
 Every center mentioned burdens in meeting the
accreditation requirements of the Foundation for
the Accreditation of Cellular Therapy (FACT) and
the unfunded federal requirements for reporting
outcomes to the Stem Cell Transplant Outcomes
Database (SCTOD).
 Recruitment of new fellows is hindered by a lack of
recognition for transplantation clinicians, a per-
ceived lack of major clinical advances in the field,
and a shortage of funding for clinical trials. Another
repeatedly mentioned concern was that the lifestyle
of transplantation physicians was not attracting
many hematology and oncology fellows, who seem
to favor outpatient specialties with fewer demands
on personal time. There also was a concern that
the expected growth in the number of patients per
transplantation physician could aggravate the nega-
tive perceptions about lifestyle.ASBMTAssistance
The survey respondents suggested the following
ways in which the ASBMT could help address these
issues:
 Seek increased funding from government and indus-
try for clinical and basic research.
 Seek funding to support required reporting of treat-
ment outcomes.
 Seek reimbursement from public and private third-
party payers for donor acquisition and typing and
for such diseases as myelodysplastic syndrome. Develop common transplantation guidelines and
requirements for third-party payers.
To help alleviate the time and resource burdens
imposed by FACT, some survey respondents sug-
gested that the ASBMT could develop templates for
standard operating procedures and quality assurance
programs. The respondents also suggested that the
ASBMT help recruit fellows and residents to the field
of transplantation and encourage those currently prac-
ticing in the field to remain active. Suggested
approaches included educational incentives, certifica-
tion of the specialty, and increased interaction among
clinicians and investigators to promote research
advances. Respondents indicated that similar recruit-
ment efforts are needed to bring physician extenders
into the transplantation field as well.
Finally, respondents recommended that the
ASBMT work to ensure that data collected by the
SCTOD are interpreted correctly. There was a con-
cern that third-party payers could use the data to pre-
clude patients from transplantation, or that centers
might turn away high-risk patients who might jeopar-
dize their treatment outcomes scores.CONCLUSION
Although this survey of transplantation centers re-
garding their ability to absorb additional patients was
neither comprehensive nor statistically representative,
it did includemost of the largest programs and a sample
of smaller programs, sufficient to give a general indica-
tion of capacity. Among the 31 centers representing
6937 transplantations performed in 2008, the esti-
mated potential for expansion was 7%. That degree
of elasticity falls well short of the expected increased
demand for transplantation. Recognition of this issue
is a critical step for the field and should help justify
the need for increased resources and incentives to
recruit and retain transplantation personnel.
The power and scope of this survey are limited.
There is a need for a formal census of transplantation
facilities, workforce activities, and compensation to
facilitate planning for anticipated growth and develop-
ing strategies for marshalling resources and recruiting
transplantation personnel.REFERENCE
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